Member Info for BaxtersSoup

Morning all

I understand that we are hopefully expecting news by EOM?

Not sure about everyone else's calendar but mine says it is the 22nd March today.

The deal done in Jan or even Feb, we know it is coming - wtf!

We are talking days not years - get a grip guys, doesn't matter

Cheers guys and Valju we have that promised lunch when you are down my way on visits. Still on the diet, lol.

The latter l guess so here we go and refreshed in the morning:

Perspective pleaseToday 21:17
Ladies and Gents
I think a little perspective is required.
In 2019, VAL was almost bankrupt with one after another toxic share raises - it was almost in liquidation.
Then a shareholder group casting the majority then extinguished the old CEO and non-productive director to give a breath of fresh air to the company.
Then Suzy put together a board that would turn the ship around with Lampshire and Treherne who has been a solid and continues to be a great serveant (he deserves a directorship IMO).
Then we had Peterhouse provide financing and the ship was in a stable check.
The company had to redirect the ship cutting costs massively and to align to new IP, with the premise that they had legacy IP.
BC201 was brought forward plus a further fantastic strategy of employing our greatest minds to introduce UK university ideas to progress new IP - the UK is the best and have the finest scientists in the world IMO.
Suzy and board made massive cost cuttings, streamlined the business to the last costing of £350k which maybe more now.
201 was a great IP and as promised it has been in principle signed off so we have a company worth £24mn today with a £66mn contract plus another £37mn for each other concept the buyer may produce plus working capital that will mean VAL won’t have to worry about the bank for several years to come if ever!
From minnow to progressive, you have on the face of it a phoenix from the fire that could be potentially be worth £10’s if no £100’s of millions IF you don’t concentrate on the here and now!
Look at the potential - VAL have only sold on one drug in principal.
Best wishes all and keep grounded.
GLA

IAR, a follower and love of the VAL concept or other?

Or maybe trying to squeeze posts before the nights out so can try and keep things negative for tomorrow?

Pop in, pop out, not my worry mate and signing out buddy!

Thats an amazing deal.

Lol OB - the deal is $61mn plus $37mn for every other cancer bolt on plus $2.2 cash upfront in instalments.
****, that’s really bad! ??????

Its gone!

What are the facts? ??????
Look at the RNS.

Yes OB, credit where credit is due, from almost liquidation to not just a going concern but now thriving and almost commercialised - brilliant!
Amazing turn of course.

The other thing that l forgot to mention is that the agreement is a master class in strategy rather than the big bio sign up up on so many levels - They are perfect for 201 on so many levels and respect the BoD decision for this. Listen to the Podcasts and you’n realise why!

Ladies and Gents
I think a little perspective is required.
In 2019, VAL was almost bankrupt with one after another toxic share raises - it was almost in liquidation.
Then a shareholder group casting the majority then extinguished the old CEO and non-productive director to give a breath of fresh air to the company.
Then Suzy put together a board that would turn the ship around with Lampshire and Treherne who has been a solid and continues to be a great serveant (he deserves a directorship IMO).
Then we had Peterhouse provide financing and the ship was in a stable check.
The company had to redirect the ship cutting costs massively and to align to new IP, with the premise that they had legacy IP.
BC201 was brought forward plus a further fantastic strategy of employing our greatest minds to introduce UK university ideas to progress new IP - the UK is the best and have the finest scientists in the world IMO.
Suzy and board made massive cost cuttings, streamlined the business to the last costing of £350k which maybe more now.
201 was a great IP and as promised it has been in principle signed off so we have a company worth £24mn today with a £66mn contract plus another £37mn for each other concept the buyer may produce plus working capital that will mean VAL won’t have to worry about the bank for several years to come if ever!
From minnow to progressive, you have on the face of it a phoenix from the fire that could be potentially be worth £10’s if no £100’s of millions IF you don’t concentrate on the here and now!
Look at the potential - VAL have only sold on one drug in principal.
Best wishes all and keep grounded.
GLA

Nice summary from the other thread:

Should be back in the 40?s and fair value now l believe is ?50mn mkt cap after yesterdays news where we will hear the details in due course, but assuming $66mn deal plus $37mn for any cancer add ons plus $2.2mn in upfront over 24 months (so no placings!) then surely even discounted is 75p all day long. GLA

Guys this was 19p weeks ago.

Get a grip and porky et al pushed it!

ReboundToday 19:30
Hi Guys, don’t post much from the early days of the gruesome twosome, but wow what a turnaround Suzy, Kevin, Mark and team have done. From pennies to tens in less than a year.
Cut costs, streamlined product IP and now a new directive in terms of woman's health - wow!
From bankrupt to stable and l have followed the growth with much admiration.
I think people are missing the point of the RNS today - multi-legacy IP in 201, 301 and 401 . 201 has been commercialised STC for $61.5mn and if it can be purposed in to other oncology IP then possible more IP for each and every cancer compound for e.g. Brain, Breast and every other cancer - can you imagine if they have 5 more applications? 5 x $31.5mn.
$2,2mm over to £350k must cover things and put the market rezt

Porky gone, massive respike upwards when people understand what VAL have achieved today -their first commercialisation.

Yes mate $61.5 is starters!

Hi Guys, don’t post much from the early days of the gruesome twosome, but wow what a turnaround Suzy, Kevin, Mark and team have done. From pennies to tens in less than a year.
Cut costs, streamlined product IP and now a new directive in terms of woman's health - wow!
From bankrupt to stable and l have followed the growth with much admiration.
I think people are missing the point of the RNS today - multi-legacy IP in 201, 301 and 401 . 201 has been commercialised STC for $61.5mn and if it can be purposed in to other oncology IP then possible more IP for each and every cancer compound for e.g. Brain, Breast and every other cancer - can you imagine if they have 5 more applications? 5 x $31.5mn.
$2,2mm over to £350k must cover things and put the market rezt

The current SP growth at circa 5-10% per day plus consolidation is exactly what any long termer would desire and not the peaks and troughs of the past. Steady away and sustainable growth will help the SP grow in phases and maintain a steady base…20’s for several months became 30’s and now 40’. Just need it slow and easy without the over-exuberance of prolific ramping.
GLA